Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

Recent & Breaking News (TSX:ONC)

Oncolytics Biotech® Inc. Announces Receipt of Nasdaq Notice of Deficiency

Canada NewsWire November 4, 2014

Oncolytics Biotech® Inc. Announces Entry Into $20 Million "At-The-Market" Equity Distribution Agreement with Canaccord Genuity Inc.

Canada NewsWire October 24, 2014

Oncolytics Biotech® Inc. Announces Amendment to Common Share Purchase Agreement with Lincoln Park Capital Fund, LLC

Canada NewsWire October 20, 2014

Oncolytics Biotech® Inc. Announces Overall and KRAS-Mutated Patient Data from U.S. Randomized Phase 2 Pancreatic Cancer Study

Canada NewsWire September 16, 2014

Oncolytics Biotech® Inc. Announces Completion of Patient Enrollment in U.S. Randomized Phase 2 Ovarian Cancer Study

Canada NewsWire September 3, 2014

Media Advisory - Oncolytics Biotech® Inc. to Participate in the Baird 2014 Health Care Conference

Canada NewsWire September 2, 2014

Media Advisory - Oncolytics Biotech® Inc. Announces Participation in Upcoming Conferences

Canada NewsWire August 11, 2014

Oncolytics Biotech® Inc. Announces Second Quarter 2014 Results

Canada NewsWire August 7, 2014

Oncolytics Biotech® Inc. Announces Completion of Patient Enrollment in U.S. Randomized Phase II Pancreatic Cancer Study

Canada NewsWire July 8, 2014

Oncolytics Biotech® Inc. Announces Director Election Results from its Annual Meeting of Shareholders

Canada NewsWire June 19, 2014

Oncolytics Biotech® Inc. Announces Details of 2014 Annual Meeting of Shareholders

Canada NewsWire June 16, 2014

Media Advisory - Oncolytics Biotech® Inc. to Participate in Jefferies 2014 Global Healthcare Conference

Canada NewsWire June 2, 2014

Oncolytics Biotech® Inc. Announces Nomination of Two New Directors

Canada NewsWire May 21, 2014

Oncolytics Biotech® Inc. Collaborators to Present Positive Brain Cancer Clinical Trial Data at the 50th Annual ASCO Meeting

Canada NewsWire May 20, 2014

Oncolytics Biotech® Inc. Announces First Quarter 2014 Results

Canada NewsWire May 8, 2014

Oncolytics Biotech Inc. Collaborators Present Preclinical Research on Liver Cancer at UK Oncolytic Virus Conference

Canada NewsWire April 14, 2014

Oncolytics Biotech Inc. Collaborators Present Head and Neck Cancer Biomarker Preclinical Research at UK Oncolytic Virus Conference

Canada NewsWire April 14, 2014

Oncolytics Biotech Inc. Collaborators Present Translational Brain Cancer Clinical Data and Immunomodulatory Preclinical Research at UK Oncolytic Virus Conference

Canada NewsWire April 11, 2014

Oncolytics Biotech® Inc. Announces Additional Data from REO 018 Randomized Study of REOLYSIN® in Head and Neck Cancers

Canada NewsWire April 8, 2014

Media Advisory - Oncolytics Biotech® Inc. to Participate in 13th Annual Needham Healthcare Conference

Canada NewsWire April 7, 2014